Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14 Meeting Abstract
| Authors: | Salwender, H.; Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R.; Byrne, J.; Eliason, L.; Scott, E.; Opalinska, J. |
| Abstract Title: | Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14 |
| Meeting Title: | 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 45 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Nov 13-16 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2022-11-01 |
| Start Page: | 173 |
| Language: | English |
| ACCESSION: | WOS:000883051700404 |
| PROVIDER: | wos |
| DOI: | 10.1159/000521004 |
| Notes: | Meeting Abstract: 991 -- Source: Wos |
